COPD-Journal of Chronic Obstructive Pulmonary Disease

metrics 2024

Advancing knowledge in respiratory health.

Introduction

COPD - Journal of Chronic Obstructive Pulmonary Disease is a premier peer-reviewed journal published by Taylor & Francis Inc. that focuses on the latest advancements in the understanding, diagnosis, and treatment of chronic obstructive pulmonary disease (COPD). As an Open Access journal since 2022, it enhances availability and dissemination of groundbreaking research, allowing researchers, healthcare professionals, and students to access vital information without barriers. The journal has established itself as a significant resource in pulmonary and respiratory medicine, boasting a commendable Q2 ranking in both medicine and specialty areas as of 2023, with an impressive Scopus rank of 66 out of 155. By bridging the gap between scientific exploration and clinical application, COPD aims to foster innovative approaches to managing this prevalent condition, making it an essential publication for those dedicated to improving patient care and advancing respiratory health.

Metrics 2024

SCIMAGO Journal Rank0.67
Journal Impact Factor2.20
Journal Impact Factor (5 years)2.40
H-Index73
Journal IF Without Self2.20
Eigen Factor0.00
Normal Eigen Factor0.40
Influence0.72
Immediacy Index0.30
Cited Half Life8.60
Citing Half Life8.80
JCI0.48
Total Documents1430
WOS Total Citations2469
SCIMAGO Total Citations9558
SCIMAGO SELF Citations420
Scopus Journal Rank0.67
Cites / Document (2 Years)2.23
Cites / Document (3 Years)2.23
Cites / Document (4 Years)2.13

Metrics History

Rank 2024

Scopus

Pulmonary and Respiratory Medicine in Medicine
Rank #66/155
Percentile 57.42
Quartile Q2

IF (Web Of Science)

RESPIRATORY SYSTEM
Rank 56/100
Percentile 44.50
Quartile Q3

JCI (Web Of Science)

RESPIRATORY SYSTEM
Rank 63/101
Percentile 37.62
Quartile Q3

Quartile History

Similar Journals

International Journal of Chronic Obstructive Pulmonary Disease

Leading the Charge Against Chronic Lung Disease
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-2005Frequency: 1 issue/year

The International Journal of Chronic Obstructive Pulmonary Disease, published by DOVE MEDICAL PRESS LTD, serves as a premier platform for researchers and professionals involved in the study and management of COPD. Established in 2006 and transitioning to an Open Access model in 2009, this journal has quickly gained a reputable standing in various impactful categories, achieving Q1 rankings in Health Policy, Medicine (Miscellaneous), and Public Health, among others. With a focus on disseminating high-quality research, the journal is pivotal for addressing global public health challenges associated with chronic obstructive pulmonary disease. The journal's dedication to open access ensures that vital information reaches a broader audience, fostering advancements in research and clinical practice. By maintaining rigorous peer-review standards and a commitment to the advancement of understanding in COPD, the journal attracts significant contributions from scientists and practitioners worldwide, making it an invaluable resource for ongoing education and research development in this critical area.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Advancing respiratory health through cutting-edge research.
Publisher: AMER THORACIC SOCISSN: 1073-449XFrequency: 24 issues/year

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

RESPIRATORY MEDICINE

Exploring Breakthroughs in Lung Health
Publisher: W B SAUNDERS CO LTDISSN: 0954-6111Frequency: 12 issues/year

Respiratory Medicine is a leading journal in the field of pulmonary and respiratory medicine, dedicated to advancing knowledge and research from 1989 to 2024. Published by W B Saunders Co Ltd, this esteemed journal is recognized for its high impact, reflected in its Q1 quartile ranking in 2023 within the category of Pulmonary and Respiratory Medicine and its impressive Scopus ranking of 27 out of 155 journals, placing it in the 82nd percentile. With a focus on publishing groundbreaking research, comprehensive reviews, and innovative practices, Respiratory Medicine serves as an essential resource for health professionals, researchers, and students aiming to improve patient outcomes and understand complex respiratory conditions. While the journal is not Open Access, its contributions to the scientific community are invaluable, providing insights that drive both academic and clinical advancements in respiratory health.

Tuberculosis and Respiratory Diseases

Uncovering breakthroughs in tuberculosis research.
Publisher: THE KOREAN ACAD TUBERCULOSIS & RESPIRATORY DISEASESISSN: 1738-3536Frequency: 4 issues/year

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

BMC Pulmonary Medicine

Connecting researchers and practitioners for impactful insights.
Publisher: BMCISSN: 1471-2466Frequency: 1 issue/year

BMC Pulmonary Medicine is a leading open access journal dedicated to the field of pulmonary and respiratory medicine, published by BMC since its inception in 2001. With an ISSN of 1471-2466, this journal plays a pivotal role in advancing knowledge and research dissemination in its field, maintaining a prominent position with a 2023 Scopus ranking of #65 out of 155 journals, placing it within the 58th percentile of the category. Based in the United Kingdom, it operates under a collaborative mission to provide unrestricted access to vital research, contributing to the global understanding of respiratory health issues. The journal is recognized for its commitment to high-quality, peer-reviewed research, as evidenced by its Q2 category designation in Pulmonary and Respiratory Medicine. BMC Pulmonary Medicine aims to foster innovation and scholarship among researchers, professionals, and students, making it an indispensable resource for anyone engaged in pulmonary research and practice. The journal, accessible to everyone, enables the dissemination of impactful research that can influence clinical practice and policy worldwide.

THORAX

Connecting researchers and clinicians for better lung health.
Publisher: BMJ PUBLISHING GROUPISSN: 0040-6376Frequency: 12 issues/year

THORAX is a premier academic journal dedicated to advancing knowledge in the field of Pulmonary and Respiratory Medicine. Published by the esteemed BMJ Publishing Group in the United Kingdom, this journal has been a pivotal resource for researchers and clinicians since its inception in 1946. With a remarkable ranking of #6 out of 155 in its category, THORAX holds a prestigious position within the top 4% of its field, as indicated by its 2023 Q1 quartile classification and a strong Scopus ranking. The journal focuses on publishing high-quality research, reviews, and clinical studies that are essential for understanding respiratory diseases and their management. Although it is not an open-access journal, THORAX provides vital contributions to the academic community, fostering dialogue and innovation in pulmonary medicine. As it approaches its converged years, concluding in 2024, researchers, professionals, and students are encouraged to explore its rich repository of knowledge, while engaging with the most current advancements in the field.

Zeitschrift fur Pneumologie

Catalyzing Change in Pulmonary Health Research
Publisher: SPRINGER HEIDELBERGISSN: 2731-7404Frequency: 6 issues/year

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

REVUE DES MALADIES RESPIRATOIRES

Illuminating the path to respiratory health advancements.
Publisher: MASSON EDITEURISSN: 0761-8425Frequency: 10 issues/year

REVUE DES MALADIES RESPIRATOIRES is a distinguished journal published by MASSON EDITEUR, focusing on the vital field of pulmonary and respiratory medicine. Established in 1984, this journal has become a prominent platform for sharing innovative research and clinical findings, reflecting an impressive array of studies that contribute to our understanding of respiratory diseases. With its ISSN 0761-8425 and E-ISSN 1776-2588, it facilitates access to scholarly work within the medical community, although it currently operates under a subscription model rather than Open Access. As indicated by its quartile ranking of Q4 in 2023 within its category and a Scopus rank of #128/155, REVUE DES MALADIES RESPIRATOIRES serves as an essential resource for researchers, professionals, and students aiming to stay informed about advancements in respiratory health. This journal plays a crucial role in fostering discussions that drive innovation and best practices in the treatment and understanding of respiratory conditions.

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine

Exploring the Frontiers of Cardiology and Pulmonology
Publisher: SAGE PUBLICATIONS LTDISSN: 1179-5484Frequency: 1 issue/year

Clinical Medicine Insights-Circulatory Respiratory and Pulmonary Medicine, published by SAGE Publications Ltd, stands as a vital resource in the fields of Cardiology and Pulmonary Medicine, underscored by its Q3 quartile rankings in both areas for 2023. Established in 2007 as an open-access journal, it facilitates the dissemination of cutting-edge research and observations from the international scientific community. With an ISSN of 1179-5484, the journal has garnered recognition for its contributions to clinical medicine, particularly covering topics of circulatory, respiratory, and pulmonary health. The journal not only aims to bridge the gap between research and clinical practice but also to serve as a platform for innovative ideas and collaborations among researchers, healthcare professionals, and trainees. By offering unrestricted access to its articles, Clinical Medicine Insights ensures that vital knowledge reaches a broad audience, ultimately fostering advancements in medical science and patient care.

Therapeutic Advances in Respiratory Disease

Pioneering Research for Better Breathing
Publisher: SAGE PUBLICATIONS LTDISSN: 1753-4658Frequency: 1 issue/year

Therapeutic Advances in Respiratory Disease is a prestigious open-access journal published by SAGE Publications Ltd, based in the United Kingdom. Since its inception in 2007, it has established itself as a leading platform for the dissemination of cutting-edge research in the fields of pulmonary and respiratory medicine and pharmacology. With an impressive impact factor and ranking—showing it is in the Q1 quartile in both Pharmacology (medical) and Pulmonary and Respiratory Medicine as of 2023—the journal's commitment to high-quality research is evident. In 2023, it ranks #32 out of 155 in Pulmonary and Respiratory Medicine and #57 out of 272 in Medical Pharmacology, positioning it in the 79th percentile across these disciplines. Open access since 2018, the journal ensures that its valuable content is readily accessible to a global audience of researchers, healthcare professionals, and students, facilitating the rapid exchange of knowledge that is crucial in the ever-evolving landscape of respiratory health. The journal's objectives include advancing understanding of respiratory diseases through innovative research and promoting the development of therapeutic strategies that improve patient outcomes, making it an essential resource for those dedicated to respiratory medicine.